Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach

[1]  Heeyoung Kim,et al.  Cognitive Trajectories and Associated Biomarkers in Patients with Mild Cognitive Impairment. , 2023, Journal of Alzheimer's disease : JAD.

[2]  P. Davis,et al.  Comorbidity‐driven multi‐modal subtype analysis in mild cognitive impairment of Alzheimer's disease , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[3]  M. Bondi,et al.  Cognitive Heterogeneity and Risk of Progression in Data-Driven Subtle Cognitive Decline Phenotypes , 2022, Journal of Alzheimer's disease : JAD.

[4]  Sterling C. Johnson,et al.  Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. , 2022, Brain : a journal of neurology.

[5]  D. Na,et al.  Development of prediction models for distinguishable cognitive trajectories in patients with amyloid positive mild cognitive impairment , 2022, Neurobiology of Aging.

[6]  M. Styner,et al.  Subtyping of mild cognitive impairment using a deep learning model based on brain atrophy patterns , 2021, Cell reports. Medicine.

[7]  D. Salmon,et al.  Data-Driven vs Consensus Diagnosis of MCI , 2021, Neurology.

[8]  W. M. van der Flier,et al.  Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity , 2021, Neurology.

[9]  Diana L. Giraldo,et al.  Quantification of cognitive impairment to characterize heterogeneity of patients at risk of developing Alzheimer's disease dementia , 2021, Alzheimer's & dementia.

[10]  A. Martínez-Torteya,et al.  Robust Discovery of Mild Cognitive impairment subtypes and their Risk of Alzheimer's Disease conversion using unsupervised machine learning and Gaussian Mixture Modeling , 2020, medRxiv.

[11]  Alan J. Thomas,et al.  Prospective predictors of decline v. stability in mild cognitive impairment with Lewy bodies or Alzheimer's disease , 2020, Psychological Medicine.

[12]  K. Bangen,et al.  Distilling Heterogeneity of Mild Cognitive Impairment in the National Alzheimer Coordinating Center Database Using Latent Profile Analysis , 2020, JAMA network open.

[13]  S. Gauthier,et al.  Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment , 2020, Alzheimer's & dementia.

[14]  D. Perani,et al.  Predicting long‐term clinical stability in amyloid‐positive subjects by FDG‐PET , 2019, Annals of clinical and translational neurology.

[15]  R. Petersen,et al.  Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging , 2017, Alzheimer's & Dementia.

[16]  D. Na,et al.  Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments , 2019, Alzheimer's Research & Therapy.

[17]  J. Hanfelt,et al.  Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center , 2018, Neurobiology of Disease.

[18]  D. Na,et al.  Prediction Models of Cognitive Trajectories in Patients with Nonamnestic Mild Cognitive Impairment , 2018, Scientific Reports.

[19]  M. Montero‐Odasso,et al.  The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review , 2018, Journal of Alzheimer's disease : JAD.

[20]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[21]  D. Salmon,et al.  Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study , 2017, Alzheimer's & dementia.

[22]  Dragan Gamberger,et al.  Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer’s disease , 2017, Scientific Reports.

[23]  M. Bondi,et al.  Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis , 2017, Journal of the International Neuropsychological Society.

[24]  Dev Mehta,et al.  Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015 , 2017, Expert opinion on investigational drugs.

[25]  F. Woon,et al.  Does mild cognitive impairment always lead to dementia? A review , 2016, Journal of the Neurological Sciences.

[26]  D. Salmon,et al.  "Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. , 2016, Journal of Alzheimer's disease : JAD.

[27]  Christophe Genolini,et al.  kml and kml3d: R Packages to Cluster Longitudinal Data , 2015 .

[28]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[29]  M. Bondi,et al.  Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors , 2015, Alzheimer's & Dementia.

[30]  Andrew Simmons,et al.  The effects of intracranial volume adjustment approaches on multiple regional MRI volumes in healthy aging and Alzheimer's disease , 2014, Front. Aging Neurosci..

[31]  Charles DeCarli,et al.  Biological heterogeneity in ADNI amnestic mild cognitive impairment , 2014, Alzheimer's & Dementia.

[32]  V. Pankratz,et al.  Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal , 2014, Neurology.

[33]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[34]  D. Salmon,et al.  Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. , 2014, Journal of Alzheimer's disease : JAD.

[35]  Wiesje M van der Flier,et al.  Progression to dementia in memory clinic patients without dementia , 2013, Neurology.

[36]  D. Salmon,et al.  Are Empirically-Derived Subtypes of Mild Cognitive Impairment Consistent with Conventional Subtypes? , 2013, Journal of the International Neuropsychological Society.

[37]  Nandini Raghavan,et al.  The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials , 2013, Alzheimer's & Dementia.

[38]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[39]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[40]  Philip S. Insel,et al.  A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment , 2012, Brain Imaging and Behavior.

[41]  B. Hyman,et al.  Amyloid-dependent and amyloid-independent stages of Alzheimer disease. , 2011, Archives of neurology.

[42]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[43]  Lisa Koski,et al.  Identifying and Characterizing Trajectories of Cognitive Change in Older Persons with Mild Cognitive Impairment , 2011, Dementia and Geriatric Cognitive Disorders.

[44]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[45]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[46]  Charles D. Smith,et al.  Modeling the Association between 43 Different Clinical and Pathological Variables and the Severity of Cognitive Impairment in a Large Autopsy Cohort of Elderly Persons , 2010, Brain pathology.

[47]  C. Jack,et al.  Mild cognitive impairment: ten years later. , 2009, Archives of neurology.

[48]  Tania Giovannetti,et al.  The heterogeneity of mild cognitive impairment: A neuropsychological analysis , 2009, Journal of the International Neuropsychological Society.

[49]  M. Bondi,et al.  Heterogeneity in mild cognitive impairment: Differences in neuropsychological profile and associated white matter lesion pathology , 2009, Journal of the International Neuropsychological Society.

[50]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[51]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[52]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[53]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[54]  R. Bartha,et al.  Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. , 2008, Brain : a journal of neurology.

[55]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[56]  Yaakov Stern,et al.  Frequency and course of mild cognitive impairment in a multiethnic community , 2008, Annals of neurology.

[57]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[58]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[59]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[60]  Yaakov Stern,et al.  Cognitive reserve and Alzheimer disease. , 2006, Alzheimer disease and associated disorders.

[61]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[62]  Charles DeCarli,et al.  Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment , 2003, The Lancet Neurology.

[63]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[64]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[65]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[66]  M N Rossor,et al.  Correlation between rates of brain atrophy and cognitive decline in AD , 1999, Neurology.

[67]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[68]  Walter Kukull,et al.  Progression to dementia in patients with isolated memory loss , 1997, The Lancet.

[69]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[70]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[71]  G. Schwarz.  Estimating the Dimension of a Model , 1978 .

[72]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.